Vistagen Expands Global Intellectual Property Portfolio With New Patents For PH80 Nasal Spray; Investigational Treatment For Migraine, Hot Flashes Due To Menopause, Premenstrual Dysphoric Disorder, And Dysmenorrhea
Vistagen Expands Global Intellectual Property Portfolio With New Patents For PH80 Nasal Spray; Investigational Treatment For Migraine, Hot Flashes Due To Menopause, Premenstrual Dysphoric Disorder,
Express News | Vistagen Therapeutics Inc: All of New Patents Are Expected to Be in Effect Until 2040
Express News | Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Mental Health America's highest national certification enhances Vistagen's ongoing efforts to promote mental health throughout the U.S. Vistagen (NASDAQ:VTGN), a clinical-stage neuroscience-focused biopharmaceutical
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q4 2024 Earnings Conference
The following is a summary of the Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript:Financial Performance:Reported a significant reduction in R&D expenses to $20 million for FY 2024
VistaGen Therapeutics | 10-K: Annual report
VistaGen Therapeutics GAAP EPS of -$1.52 Misses by $1.16, Revenue of $1.06M Beats by $0.86M
Vistagen Reports FY24 Net Loss Of $(29.4)M Vs $(59.2)M Last Year
Cash and cash equivalents were $119.2 million as of March 31, 2024.
Express News | Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
VistaGen Therapeutics Q4 Earnings Preview
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it
Vistagen to Present at the Jefferies Global Healthcare Conference
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced
30 Countries With the Lowest Depression Rates
This Overlooked Corner of Women's Health Could Be a $350 Billion Market Opportunity
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.